Pulse Biosciences' nPulse(TM) Vybrance(TM) System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
MWN-AI** Summary
Pulse Biosciences, Inc. (Nasdaq: PLSE) will showcase its innovative nPulse™ Vybrance™ System at the Annual North American Society for Interventional Thyroidology Meeting on March 6-7, 2026, in Portland, Oregon. The system utilizes Nanosecond Pulsed Field Ablation (nsPFA™) technology for soft tissue ablation, specifically targeting benign thyroid nodules. The presentations will highlight promising long-term follow-up data from the nPulse Vybrance feasibility study, which has monitored patients for up to 22 months, reflecting the system's potential effectiveness.
Co-Chairman Paul LaViolette emphasized the company's gratitude towards the research teams, including Prof. Stefano Spiezia and his colleagues from Ospedale del Mare in Naples, for their contributions to advancing thyroid nodule treatments. The meeting includes a clinical session featuring an interim report on the feasibility study, focusing on the durability of volume and symptom reduction in treated patients. Additionally, a roundtable presentation will discuss the nonthermal ablation capabilities of the nsPFA technology, covering its mechanisms, clinical outcomes, and user experiences.
Pulse Biosciences aims to transform healthcare through its proprietary technology, which delivers short bursts of electrical energy to clear unhealthy cells while preserving adjacent tissues. Beyond thyroid ablation, the company is exploring applications in atrial fibrillation and other medical areas with the potential for significant patient impact.
While the company is optimistic about the results shared at this event, it also emphasizes that these outcomes are forward-looking and subject to uncertainties. Investors are encouraged to consider risks mentioned in the company's SEC filings and to stay updated on new developments. Overall, the nPulse Vybrance System exemplifies innovative approaches in the treatment of benign thyroid conditions.
MWN-AI** Analysis
Pulse Biosciences, Inc. (Nasdaq: PLSE) is generating buzz in the healthcare investment community with its innovative nPulse™ Vybrance™ System, designed for soft tissue ablation, particularly for benign thyroid nodules. With its upcoming presentations at the North American Society for Interventional Thyroidology (NAST) meeting in March 2026, investors should take note of the potential impact of this technology on the healthcare landscape.
The nPulse technology utilizes proprietary Nanosecond Pulsed Field Ablation™ (nsPFA) energy, which is gaining traction due to its ability to non-thermally ablate cells while sparing adjacent tissue. This unique mechanism is particularly relevant in the treatment of benign thyroid nodules, a prevalent condition affecting many. Long-term follow-up data from the feasibility study—presented at the NAST conference—will likely bolster confidence in the efficacy and durability of the treatment. With patient follow-ups of up to 22 months, this data could be pivotal in establishing its market viability.
The involvement of notable figures like Prof. Stefano Spiezia and endorsements from clinical practitioners enhance the credibility of the nPulse technology. The prospect of further market disruption, especially if compelling data supports the safety and effectiveness of the system, presents a solid investment opportunity. However, it's essential for investors to carefully consider the associated forward-looking statements that highlight both opportunities and risks.
Looking ahead, Pulse Biosciences' ongoing commitment to refining its technology for broader applications, including conditions like atrial fibrillation, could position the company as a significant player in the bioelectric medicine market. Given the potential clinical benefits and positive investor sentiment surrounding its upcoming presentations, Pulse Biosciences warrants close attention as it navigates this critical juncture in its development trajectory. Potential investors should monitor the outcomes of these presentations closely and assess how this technology aligns with broader trends in non-invasive medical treatments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
nPulse™ Vybrance™ System for soft tissue ablation, such as benign thyroid ablation, to be highlighted in podium presentation and product theatre presentation
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a podium presentation and a product theatre presentation at the Annual North American Society for Interventional Thyroidology 2026 meeting, being held March 6-7 in Portland, Oregon.
“We are pleased to share promising long-term follow up data for patients treated in the nPulse Vybrance feasibility study, with patients now having been followed for up to 22 months,” said Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors. “We would like to thank Prof. Stefano Spieza, the team at Ospedale del Mare in Naples, Italy, and our nPulse Vybrance investigators for continuing to advance the treatment of benign thyroid nodules with nsPFA technology. We look forward to engaging with the entire clinical community at this important meeting. Much work and analysis remains to be managed.”
Key nPulse Technology Scientific Programming
Friday, March 6 th
- 4:40pm, Prof. Stefano Spiezia – Clinical Science Session
- Title: Interim Report: Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation – Durability of Volume and Symptom Reduction
- Review of the long-term follow up at 15-22 months for patients treated in the initial feasibility study of nPulse Vybrance technology used for the ablation of benign, symptomatic thyroid nodules
Saturday, March 7 th , Product Theatre Presentation
- 7:00-7:45am, Ralph Tufano, MD, Prof. Stefano Spiezia, Emad Kandil, MD, Kepal Patel, MD
- Title: nPulse Technology – the Potential of Nonthermal Ablation with nsPFA Energy is a work in process
- Roundtable presentation by top nPulse users on the technology, mechanism of action, results, and case studies of the use of nPulse Vybrance technology for benign, symptomatic thyroid nodules
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nPulse Vybrance System, the nPulse Cardiac Clamp System, and the nPulse Cardiac Catheter System, statements concerning disruptive market opportunities and the Company’s commercial plans, customer adoption and future use of the nPulse System to address a range of conditions such as benign thyroid nodules, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304420851/en/
Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
FAQ**
What are the key competitive advantages of the nPulse™ technology developed by Pulse Biosciences Inc. (PLSE) compared to existing treatments for benign thyroid ablation?
How does the ongoing clinical feasibility study support the long-term efficacy of the nPulse Vybrance System, and what are the implications for future applications by Pulse Biosciences Inc. (PLSE)?
What feedback do clinicians have regarding the nPulse Vybrance technology's mechanism of action and clinical outcomes as discussed during the Annual North American Society for Interventional Thyroidology meeting involving Pulse Biosciences Inc. (PLSE)?
How does Pulse Biosciences Inc. (PLSE) plan to address potential market risks and uncertainties associated with the adoption of the nPulse technology in soft tissue ablation procedures?
**MWN-AI FAQ is based on asking OpenAI questions about Pulse Biosciences Inc (NASDAQ: PLSE).
NASDAQ: PLSE
PLSE Trading
-1.04% G/L:
$18.05 Last:
69,356 Volume:
$18 Open:
